US EditionPublished • loading... • Updated
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for ...
Royalty Pharma will fund up to $500 million to accelerate Teva's anti-IL-15 antibody TEV-408 development for vitiligo, including $75 million for Phase 2b starting in 2026.
Summary by Inside Ottawa Valley
7 Articles
7 Articles
The company signed an agreement of up to $500 million with Royalty Pharma to develop a drug for vitiligo that will enter phase 2 of clinical trials. • This year, it expects similar revenues or a slight decrease compared to 2025, along with an increase in profitability and free cash flow, and in 2027, growth in revenues, profitability and cash flow.
Hastings TribuneReposted by 
The Manila Times
The Manila TimesTeva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for ...
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo…
Coverage Details
Total News Sources7
Leaning Left1Leaning Right2Center3Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 17%
C 50%
R 33%
Factuality
To view factuality data please Upgrade to Premium
